Pacific Biosciences Beats Q4 Estimates with $45M Revenue and $0.12 Loss
Pacific Biosciences posted fourth-quarter 2025 adjusted loss of $0.12 per share, 36.8% above estimates, and generated $45 million in revenue, 9.4% ahead of consensus. It has surpassed targets in each of the past four quarters with 27.7% average earnings surprises but anticipates a 1.9% EPS decline versus 11.4% industry growth.
1. Q4 2025 Financial Results
Pacific Biosciences recorded an adjusted loss of $0.12 per share for fourth-quarter 2025, surpassing consensus by 36.8%, and reported revenue of $45 million, a 9.4% beat.
2. Consecutive Estimate Beats
The company has exceeded analyst targets in each of the last four quarters, delivering an average earnings surprise of 27.7%, underscoring consistent operational performance.
3. Outlook and Comparative Trends
Despite recent outperformance, Pacific Biosciences faces a projected 1.9% decline in 2026 earnings per share compared with an 11.4% increase for the broader industry, indicating potential headwinds ahead.